Jill and Alan Miller Associate Professor in Breast Cancer Excellence, Associate Professor in Medicine and Epidemiology, Co-Leader, Breast Cancer Program, Abramson Cancer Center, University of Pennsylvania
Oncology
Dr. Angela Demichele, MD
|
|
Give Review
Doctor Angela Demichele, MD is an expert in the field of Oncology. She went to Washington University School of Medicine in St. Louis. She received awards:"CMS Meaningful Use Stage 1 Certification", "Advancing Innovation Award (DeMichele, ISPY/TRANSCEND Team Team Co-Investigator)", "Alavi Award for Excellence in Cancer Research", "Recipient, FOCUS Award for Research in Women's Health", "Recipient, Best Poster Award", "Otto Haas Jr. Faculty Fellow Award", "Loan Repayment Program for Clinical Research Awardee", "Research Foundation Award", "Young Investigator Award", "Institutional Research Award", "Workshop Scholarship Recipient", "Robert Carter Award", "Gina Finzi Memorial Fellowship", "Four Schools Physician Scientist Program Scholarship Recipient", "Sigma Xi Honorary Research Society", "Transfusion Medicine Student Award" and "Summer Research Assistantship Award". Angela Demichele, MD is also a published physician. She has 92 paper published. The most recent paper is: Detection of antitrophoblast antibodies in the sera of patients with anticardiolipin antibodies and fetal loss. Angela Demichele accepts all Medicare patients.
Publications
- Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring.
- Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
- Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.
- Black breast Cancer survivors experience greater upper extremity disability.
- "Braking" the Cycle of Resistance in Endocrine Therapy for Breast Cancer.
- The Neoadjuvant Model is Still the Future for Drug Development in Breast Cancer.
- Prevalence of mutations in a panel of breast Cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast Cancer.
- CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety and Predictive Biomarker Assessment.
- Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast Cancer patients.
- Electroacupuncture for fatigue, sleep, and psychological distress in breast Cancer patients with aromatase inhibitor-related arthralgia: A randomized trial.
- A hybrid effectiveness-implementation trial of an evidence-based exercise intervention for breast Cancer survivors.
- Deformable registration for quantifying longitudinal tumor changes during neoadjuvant chemotherapy.
- Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid Tumors and melanoma.
- Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid Tumors and melanoma.
- Expectancy in real and sham acupuncture: does believing make it so?
- Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast Cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657).
- Accelerated Approval for Pertuzumab in the Neoadjuvant Setting: Winds of Change?
- Metrics to evaluate treatment summaries and survivorship care plans: A scorecard.
- A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use.
- Validation of quickDASH outcome measure in breast Cancer survivors for upper extremity disability.
- Par-4 Downregulation Promotes Breast Cancer Recurrence by Preventing Multinucleation following Targeted Therapy.
- Impact of Chemotherapy-Induced Peripheral Neuropathy on Treatment Delivery in Nonmetastatic Breast Cancer.
- Erratum to: Impact of breast Cancer on anti-mullerian hormone levels in young women.
- Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials.
- mir-30d Regulates multiple genes in the autophagy pathway and impairs autophagy process in human Cancer cells.
- Impact of breast Cancer on anti-mullerian hormone levels in young women.
- Optical malignancy parameters for monitoring progression of breast Cancer neoadjuvant chemotherapy.
- A genome-wide association study of breast Cancer in women of African ancestry.
- Evaluating the Impact of New Imaging Tests: Promises and Pitfalls.
- Taste alteration in breast Cancer patients treated with taxane chemotherapy: experience, effect, and coping strategies.
- CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients.
- Prevalence and risk factors for insomnia among breast Cancer patients on aromatase inhibitors.
- Vitamin d deficiency in postmenopausal breast Cancer survivors.
- Risk management in BRCA1 and BRCA2 mutation carriers: lessons learned, challenges posed.
- Multicenter phase II study of oral bexarotene for patients with metastatic breast Cancer.
- Older age predicts a decline in adjuvant chemotherapy recommendations for patients with Breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible...
- Nutritional approaches to late toxicities of adjuvant chemotherapy in breast Cancer survivors.
- Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast Cancer.
- Distress, psychiatric morbidity, and prescriptions for psychotropic medication in a breast Cancer waiting room sample.
- Experience of trauma, distress, and posttraumatic stress disorder among breast Cancer patients.
- Morbidity and mortality of coloRectal carcinoma surgery differs by insurance status.
- Immune responses of breast Cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R).
- Early bacteremia in pediatric hematopoietic stem cell transplant patients on oral antibiotic prophylaxis.
- Diffuse optical tomography of breast Cancer during neoadjuvant chemotherapy: a case study with comparison to MRI.
- Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women.
- Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast Cancer cohort.
- Ethnic disparities in adjuvant chemotherapy for breast Cancer are not caused by excess toxicity in black patients.
- Cancer survivorship--genetic susceptibility and second primary Cancers: research strategies and recommendations.
- The impact of HER-2 status on local recurrence in women with stage I-II breast Cancer treated with breast-conserving therapy.
- Estrogen sulfation genes, hormone replacement therapy, and endometrial Cancer risk.
- Case-control study of postmenopausal hormone replacement therapy and endometrial Cancer.
- A retrospective case-control study of the use of hormone-related supplements and association with breast Cancer.
- Targeting HER-2/neu in early breast Cancer development using dendritic cells with staged interleukin-12 burst secretion.
- Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast Cancer etiology.
- Lack of effect modification between estrogen metabolism genotypes and combined hormone replacement therapy in postmenopausal breast Cancer risk.
- Telomerase-specific T-cell immunity in breast Cancer: effect of vaccination on tumor immunosurveillance.
- In response to "Drug metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast Cancer cohort".
- Experiences with weight change in African-American breast Cancer survivors.
- Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian Cancer.
- Impact of raloxifene or tamoxifen use on endometrial Cancer risk: a population-based case-control study.
- Hormone-dependent effects of FGFR2 and MAP3K1 in breast Cancer susceptibility in a population-based sample of post-menopausal African-American and European-American wo...
- Lymphedema in breast Cancer survivors: incidence, degree, time course, treatment, and symptoms.
- Two estrogen-related variants in CYP19A1 and endometrial Cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium.
- Delivery of survivorship care by primary care physicians: the perspective of breast Cancer patients.
- Colon Cancer patient information seeking and the adoption of targeted therapy for on-label and off-label indications.
- Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast Cancer survivors.
- Differentiation of benign and malignant Breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomography.
- Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast Cancer.
- Optically measured microvascular blood flow contrast of malignant Breast tumors.
- Optimizing outcomes with bevacizumab by better targeting patients and Tumors.
- Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast Cancer survivors.
- Genomic predictors of outcome and treatment response in breast Cancer.
- Feasibility trial of electroacupuncture for aromatase inhibitor--related arthralgia in breast Cancer survivors.
- Immuno-modulatory gene polymorphisms and outcome in breast and ovarian Cancer.
- Adult Cancer survivorship: evolution, research, and planning care.
- Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast Cancer survivors.
- Weight gain is associated with increased risk of hot flashes in breast Cancer survivors on aromatase inhibitors.
- The expanding role of bevacizumab in the treatment of human epidermal growth factor receptor 2-negative breast Cancer.
- Computer aided automatic detection of Malignant lesions in diffuse optical mammography.
- Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast Cancer: a retrospective cohort study.
- Cyclin D1b in human Breast carcinoma and coexpression with cyclin D1a is associated with poor outcome.
- Differences in information seeking among breast, prostate, and colorectal Cancer patients: results from a population-based survey.
- Risk factors for lymphedema after breast Cancer treatment.
- Predictors of yoga use among patients with breast Cancer.
- Cancer information scanning and seeking in the general population.
- Antral follicle count provides additive information to hormone measures for determining ovarian function in breast Cancer survivors.
- Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast Cancer survivors.
- A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast Cancer.
- The role of lapatinib in the preoperative therapy of breast Cancer.
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer.
- Detection of antitrophoblast antibodies in the sera of patients with anticardiolipin antibodies and fetal loss.
Schools
Washington University St Louis
Hospital Of The University Penn
University Penn Cancer Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Advancing Innovation Award (DeMichele, ISPY/TRANSCEND Team Team Co-Investigator)
- Alavi Award for Excellence in Cancer Research
- Recipient, FOCUS Award for Research in Women's Health
- Recipient, Best Poster Award
- Otto Haas Jr. Faculty Fellow Award
- Loan Repayment Program for Clinical Research Awardee
- Research Foundation Award
- Young Investigator Award
- Institutional Research Award
- Workshop Scholarship Recipient
- Robert Carter Award
- Gina Finzi Memorial Fellowship
- Four Schools Physician Scientist Program Scholarship Recipient
- Sigma Xi Honorary Research Society
- Transfusion Medicine Student Award
- Summer Research Assistantship Award
Education
-
University of Pennsylvania Health System -
Washington University School of Medicine in St. Louis -
Brown University
Hospital
-
Hospital of the University of Pennsylvania
Drug Facts
| NPI NUMBER | 1528099322 | |
| NPPES Provider LastName | DEMICHELE | |
| NPPES Provider FirstName | ANGELA | |
| NPPES Provider ZIPCode | 19104 | |
| NPPES Provider State | PA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 105.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1528099322 |
| Last Name Of The Provider | DEMICHELE |
| First Name Of The Provider | ANGELA |
| View All |
Similar Doctors
|
|
Dr. Jonathan D. Cheng, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason Palopoli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Frederick G. Dold, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan M. Domchek, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Julia Kennedy, DO |
|
|
Dr. Anjana Ranganathan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Naomi S. Haas, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Christina Brus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen M. Hahn, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Anna C. Lysiak, MD
This Doctor is OpenDoctor Recommended.
|